A composition for the controlled release of a nucleic acid such as short interfering RNA or messenger RNA,comprising silicon nanoparticles, at least one amino acid,and at least one lipid, wherein the silicon nanoparticles comprise at least 50% by weight silicon. Also related compositions and methods.

The invention provides solid lipid nanoparticles (SLNs) which comprise gold, and are useful as vectors for the transfection of different types of nucleic acids. Different methods for obtaining such SLNs are also disclosed.

Ayurvedic encapsulated gold nanoparticles, methods of fabrication and methods of treatment are provided. A method of fabrication includes mixing dried gooseberry product or mango peel product or phytochemical existent therein, into a liquid medium to form a reducing agent solution. Gold salts are mixed into the reducing agent solution. Reaction of the gold salts proceeds, in the absence of any other reducing agent, to form a nanoparticle solution of stabilized, biocompatible Ayurvedic encapsulated gold nanoparticles. An Ayurvedic medicine consists of a non-radioactive gold nanoparticle encapsulated with phytochemical existent in mango peal or gooseberry in a capsule with curcumin extract and gum Arabic.

A multidimensional nanoconstruct includes a three-dimensional thiolated protein, gelatin or polymer nanoparticle and exposed metallic nanoparticles bonded to outer surfaces of the particle. In a method of formation, number of metallic nanoparticles that attach to the carrier nanoparticle is controlled via microfluidics or via controlling the reactivity of the metallic nanoparticle and carrier nanoparticle.

A contact lens product having a cornea repair function includes a composition in the form of a solution. The composition includes gold nanoparticles and at least one auxiliary repairing ingredient. The gold nanoparticles are present in an effective concentration from 0.01 ppm to 3000 ppm and have an average particle size from 0.01 nm to 100 nm. The at least one auxiliary repairing ingredient is selected from the group consisting of chondroitin sulfate, α-lipoic acid, 2-aminoethanesulfonic acid, and potassium L-aspartate and present in an amount greater than 0 wt % and less than 20 wt % based on the composition being 100 wt %.

One compound (100) according to the present invention contains silicon fine particles having a capability of generating hydrogen or aggregates of the silicon fine particles. The compound that contains the silicon fine particles or the aggregates having a capability of generating hydrogen is capable of generating hydrogen in the body of, for example, an animal that has ingested the compound. For a plant, the compound can be disposed or charged into, for example, moisture (water-containing liquid) or fertilizer to be provided to the plant, to supply the plant with hydrogen generated from the compound.

Certain embodiments are directed to compositions and related methods for oral delivery of compositions for effective administration of leptin pathway modulating agents (e.g., leptin, anti-leptin antibodies, anti-leptin receptor antibodies and the like), the composition including an ionic liquid (e.g., CAGE) or a beta-glucan composition and a leptin pathway modulator for reducing or maintaining body weight. In certain aspects the leptin pathway modulator is leptin or an anti-leptin antibody. An ionic liquid (IL) is a salt in the liquid state.

The subject invention provides materials and methods for intracellular deliver of molecules and/or therapeutic agents. The subject invention also provides methods for synthesizing polymeric systems and nanomaterials that enhance or assist the passage of molecules and/or therapeutic agents across biological membranes. The compound, polymer or nanoparticle of the subject invention comprises a modified guanidine moiety in a plurality of repeating units of a polymer or on the surface of a nanoparticle where the guanidine moiety comprises, for example, a carbamoyl or thiourea modification. The polymer or nanoparticle can be used in a cancer treatment formulation.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

Methods disclosed herein provide for an environmentally-friendly approach that employ citric extracts from fruits as unique reducing and stabilizing agents for making a tellurium nanomaterial. A particular method of making a tellurium nanomaterial includes combining citrus fruit extract with a tellurium salt to form a mixture of citrus fruit extract and dissolved tellurium salt; and heating the mixture of citrus fruit extract and dissolved tellurium salt, thereby making the tellurium nanomaterial. The resulting nanoparticles exhibit enhanced and desirable biomedical properties toward treatment of both infectious diseases and cancer.